7-methoxy-3-(4-(oxiran-2-ylmethoxy)phenyl)-4H-chromen-4-one | 1182706-73-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 7-methoxy-3-(4-(oxiran-2-ylmethoxy)phenyl)-4H-chromen-4-one
• 英文别名: 7-methoxy-3-(4-oxiranylmethoxy-phenyl)-4H-chromen-4-one；7-Methoxy-3-[4-(oxiran-2-ylmethoxy)phenyl]-4H-chromen-4-one；7-methoxy-3-[4-(oxiran-2-ylmethoxy)phenyl]chromen-4-one
• CAS: 1182706-73-5
• 化学式: C₁₉H₁₆O₅
• 分子量: 324.333
• InChiKey: OVIDDBRVGYWHOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  57.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-methoxy-3-(4-(oxiran-2-ylmethoxy)phenyl)-4H-chromen-4-one 、 环丙胺 以 乙醇 为溶剂， 反应 4.0h， 以78%的产率得到3-(4-(3-(cyclopropylamino)-2-hydroxypropoxy)phenyl)-7-methoxy-4H-chromen-4-one
  参考文献：
  名称：

  ISOFLAVONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

  摘要：

  提供了一种异黄酮衍生物。该异噁唑衍生物具有以下结构式：其中R1和R2独立地包括C1-C12烷基，可选择地取代为环氧丙烷、硫代环氧丙烷、环氮丙烷、氨基、环氨基、氨基羟基或环氨基羟基；R3包括氢、羟基或C1-C12烷氧基，可选择地取代为环氧丙烷、硫代环氧丙烷、环氮丙烷、氨基、环氨基、氨基羟基或环氨基羟基。该发明还提供了一种用于治疗骨质疏松症的药物组合物，包括一种异黄酮衍生物或其药用盐以及一种药学上可接受的载体。

  公开号：

  US20090215767A1
• 作为产物：
  描述：

  1-(2-羟基-4-甲氧基苯基)-2-(4-羟基苯基)乙酮 在 三氟化硼乙醚 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 10.0h， 生成 7-methoxy-3-(4-(oxiran-2-ylmethoxy)phenyl)-4H-chromen-4-one
  参考文献：
  名称：

  Synthetic analogs of daidzein, having more potent osteoblast stimulating effect

  摘要：

  A series of didzein derivatives were synthesized and assessed for stimulation of osteoblast differentiation using primary cultures of rat calvarial osteoblasts. Data suggested that three synthetic analogs, 1c, 3a and 3c were several folds more potent than daidzein in stimulating differentiation and mineralization of osteoblasts. Further, these three compounds did not show any estrogen agonistic activity, however had mild estrogen antagonistic effect. Out of the three compounds, 3c was found to maximally increase the mineralization of bone marrow osteoprogenitor cells. Compound 3c also robustly increased the mRNA levels of osteogenic genes including bone morphogenetic protein-2 and osteocalcin in osteoblasts. Unlike daidzein, 3c did not inhibit osteoclastogenesis. Collectively, we demonstrate osteogenic activity of daidzein analogs at significantly lower concentrations than daidzein. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.008

文献信息

• Isoflavone derivatives and pharmaceutical compositions comprising the same
  申请人：Kaosiung Medical University

  公开号：US07618998B2

  公开（公告）日：2009-11-17

  An isoflavone derivative is provided. The isoxazole derivative has following formula: wherein R1 and R2, independently, include C1-C12 alkyl optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy, and R3 includes hydrogen, hydroxy or C1-C12 alkoxy optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy. The invention also provides a pharmaceutical composition for treatment of osteoporosis including an isoflavone derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

  提供一种异黄酮衍生物。该异噁唑衍生物具有以下式子：其中R1和R2，独立地，包括C1-C12烷基，可选地取代氧环丙烷、硫环丙烷、氮杂环丙烷、氨基、环氨基、氨基羟基或环氨基羟基；R3包括氢、羟基或C1-C12烷氧基，可选地取代氧环丙烷、硫环丙烷、氮杂环丙烷、氨基、环氨基、氨基羟基或环氨基羟基。本发明还提供了一种用于治疗骨质疏松症的药物组合物，包括一种异黄酮衍生物或其药学上可接受的盐和药学上可接受的载体。
• Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives
  作者：Chih-Hua Tseng、Yeh-Long Chen、Chih-Ming Lu、Chih-Kuang Wang、Yin-Tung Tsai、Ru-Wei Lin、Chain-Fu Chen、Yu-Fang Chang、Gwo-Jaw Wang、Mei-Ling Ho、Cherng-Chyi Tzeng

  DOI：10.1016/j.ejmech.2009.02.025

  日期：2009.9

  We report herein the synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives. The results indicated that 3-(3,4-dimethoxyphenyl)-7-(oxiran-2-ylmethoxy)-4H-chromen-4-one (4) and 3-4-[3-(cyclohexylamino)-2-hydroxypropoxy]phenyl}-7-methoxy-4H-chromen-4-one (5a) exhibited significant inhibitory effects on osteoclast activity (TRAP activity in RAW 264.7 with an ED50 of 0.56 and 2.28 mu M respectively). Both compounds have also exhibited very strong osteogenic effects, approximately a 10-fold effect of Ipriflavone on mineralization of osteoblasts; (MC3T3E1 cells, a preosteoblast cell line derived from calvaria of C57BL/6 mice). Results indicated the potency on enhancing mineralization in D1 cells (a bone marrow mesenchymal cell line derived from BALB/c mice) decreased in an order 4 > Ipriflavone > Sa. However, the potency on enhancing mineralization in human adipose tissue derived stem cells (hADSCs) decreased in an order Sa > 4 > Raloxifene > Ipriflavone. Compound 5a has been found to be non-cytotoxic and especially active in the enhancement of mineralization in human adipose tissue derived stem cells. Therefore, Sa was selected as a potential lead for further structural optimization. (C) 2009 Published by Elsevier Masson SAS.
• US7618998B2
  申请人：——

  公开号：US7618998B2

  公开（公告）日：2009-11-17